Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METRONIDAZOLE vs ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
After entry into the cell, metronidazole is reduced by bacterial nitroreductases to form toxic metabolites that damage DNA and inhibit nucleic acid synthesis, leading to cell death.
Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.
Trichomoniasis,Bacterial vaginosis,Amebiasis,Giardiasis,Anaerobic bacterial infections (e.g., intra-abdominal, gynecologic, skin and soft tissue, bone and joint, CNS infections),Helicobacter pylori eradication (in combination therapy),Perioperative prophylaxis for colorectal surgery,Acute diverticulitis,Crohn's disease (off-label),Rosacea (topical),Decubitus ulcers (topical)
Treatment of acute attacks of vivax malaria due to Plasmodium vivax,Radical cure of vivax malaria (elimination of hypnozoites),Suppression of malaria (prophylaxis) in areas with chloroquine-sensitive P. vivax
500 mg intravenously every 8 hours or 500 mg orally every 8 hours; for bacterial vaginosis, 500 mg orally twice daily for 7 days; for trichomoniasis, 2 g orally as a single dose.
Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.
8 hours (range 6-10 hours) in adults; prolonged to 18-20 hours in severe hepatic impairment; requires adjustment in cirrhosis.
Chloroquine: 40-60 days (terminal); Primaquine: 6-8 hours (terminal). Clinical context: chloroquine accumulates extensively, requiring prolonged monitoring for toxicity; primaquine, shorter half-life, once-daily dosing.
Hepatic metabolism via oxidation and glucuronidation; major cytochrome P450 enzymes: CYP2A6, CYP3A4, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1; also reduced by nitroreductases in some bacteria and human cells.
Chloroquine: hepatic metabolism via CYP2C8 and CYP3A4; primaquine: hepatic metabolism via CYP2D6 and other enzymes.
Renal (60-80% unchanged drug), biliary/fecal (6-15% as metabolites, <20% unchanged).
Renal: 70% (chloroquine as unchanged drug and metabolites), 20% (primaquine as metabolites); Fecal: ~10% (chloroquine); Biliary: minor for both.
<20% bound to plasma proteins (albumin).
Chloroquine: 50-65% bound to albumin; Primaquine: ~20% bound to albumin.
0.7-1.1 L/kg; Vd increased in edema/ascites; distributes widely including CNS, bone, and abscess cavities.
Chloroquine: Vd 100-200 L/kg (extensive tissue distribution); Primaquine: Vd 3-5 L/kg (moderate distribution). Clinical meaning: large Vd of chloroquine indicates deep tissue compartments with slow release.
Oral: 80-95% (100% for immediate-release); Topical: <2% systemic; Vaginal: 20-25% systemic after 500 mg dose.
Both: Oral bioavailability ~80-90% for chloroquine; ~90% for primaquine. No parenteral form for this combination.
For GFR 10-50 m L/min: no adjustment needed; for GFR <10 m L/min: extend interval to every 12 hours if using multiple doses; for intermittent hemodialysis: administer dose after dialysis on dialysis days.
For chloroquine: GFR 10-50: 50% dose; GFR <10: 25% dose. For primaquine: No adjustment required, but monitor for hemolysis in GFR <10 due to accumulation.
For Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: use with caution, consider further dose reduction (e.g., 50% of normal dose every 12 hours) and monitor for toxicity.
For chloroquine: Child-Pugh A/B: no adjustment; Child-Pugh C: reduce dose by 50% or avoid. For primaquine: Child-Pugh A/B: no data, use with caution; Child-Pugh C: contraindicated due to risk of hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency and impaired clearance.
Neonates: 15 mg/kg loading dose, then 7.5 mg/kg every 12 hours for <7 days, or every 8 hours for 7-28 days; Infants and children: 7.5 mg/kg every 6 hours (max 4 g/day) for most infections; for amebiasis: 35-50 mg/kg/day in 3 divided doses for 10 days.
Chloroquine: 10 mg base/kg orally once daily for 2 days, then 5 mg base/kg once daily (max 300 mg base/day) for 2 weeks. Primaquine: 0.5 mg base/kg orally once daily for 14 days (max 30 mg base/day). Ensure G6PD screening before use.
No specific dose adjustment based solely on age, but monitor renal function; reduce dose if creatinine clearance <10 m L/min as per renal adjustment; use lowest effective dose and monitor for neurotoxicity (e.g., peripheral neuropathy, seizures).
Use lower end of adult dose for chloroquine due to reduced renal function; adjust according to Cr Cl. For primaquine, monitor for G6PD deficiency and hemolysis; dose as per adult. Consider increased risk of QT prolongation with chloroquine.
Carcinogenicity has been observed in mice and rats following chronic administration; however, the relevance to humans is unclear.
Primaquine may cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Test for G6PD deficiency before starting therapy.
May cause peripheral neuropathy and CNS effects including seizures, dizziness, and ataxia; discontinue if abnormal neurologic signs occur.,Carcinogenicity in animal studies; use for shortest duration necessary.,Hepatotoxicity and pancreatitis reported.,Hypersensitivity reactions including Stevens-Johnson syndrome.,May prolong QT interval; use with caution in patients with electrolyte disturbances or taking other QT-prolonging drugs.,Potential for disulfiram-like reaction with alcohol; avoid during therapy and for at least 48 hours after completion.,Possible mutagenicity; avoid use in pregnancy (especially first trimester) unless clearly needed.,May cause metallic taste, nausea, and other GI disturbances.
Hemolytic anemia (especially G6PD deficiency), bone marrow suppression, prolonged QT interval, visual disturbances (retinopathy with chloroquine), methemoglobinemia, and severe hypersensitivity reactions.
Hypersensitivity to metronidazole or other nitroimidazole derivatives,First trimester of pregnancy (theoretical risk, though risk appears low),Concomitant use with disulfiram (can cause acute psychosis/confusion),Concomitant use with ethanol or propylene glycol (disulfiram-like reaction)
G6PD deficiency (primaquine), known hypersensitivity to chloroquine or primaquine, porphyria, concurrent use of drugs with known hemolytic potential, pregnancy (based on risk-benefit), and severe liver or kidney disease.
Avoid alcohol and alcohol-containing foods (e.g., sauces, vinegars, some desserts) during therapy and for 48 hours after completion. No other significant food interactions.
No clinically significant food interactions reported. However, antacids containing magnesium or aluminum can reduce chloroquine absorption; separate administration by at least 4 hours. Grapefruit juice may increase chloroquine levels via CYP3A4 inhibition; avoid concurrent use.
Metronidazole crosses the placenta. First trimester: limited human data show no consistent increase in major malformations; however, some studies suggest a possible small risk of oral clefts. Second/third trimester: generally considered low risk; no known fetal toxicity at standard doses. Avoid high doses in first trimester unless essential.
In first trimester, chloroquine is generally considered low risk for major malformations, but primaquine is contraindicated due to risk of hemolytic anemia in G6PD-deficient fetuses. Second and third trimesters: chloroquine is safe, but primaquine should be avoided as fetal G6PD status is unknown.
Metronidazole is excreted into breast milk with an M/P ratio of approximately 0.9. Peak milk concentration occurs 2-4 hours after dose. After single 2 g dose, withholding breastfeeding for 12-24 hours is recommended. Chronic use: monitor infant for diarrhea, candidiasis, or irritability.
Chloroquine is excreted into breast milk in low concentrations; M/P ratio is approximately 0.5-0.6. Primaquine is excreted in breast milk; M/P ratio not well established. Breastfeeding is generally considered safe if infant is G6PD normal, but caution is advised due to potential for hemolysis in G6PD-deficient infants.
No specific dose adjustment required in pregnancy; pharmacokinetics unchanged. Standard adult dosing applies. For bacterial vaginosis: 500 mg PO BID x 7 days or 2 g single dose. Avoid high-dose regimens (e.g., for trichomoniasis) in first trimester; use clotrimazole locally if possible.
Chloroquine: No dose adjustment required; pharmacokinetics are not significantly altered. Primaquine: Contraindicated in pregnancy due to risk of hemolytic anemia in the fetus; no dose adjustment is applicable as it is not recommended.
Metronidazole is a nitroimidazole antibiotic effective against anaerobic bacteria and protozoa. It requires acidic environment for activation; thus, avoid concurrent use with antacids or H2 blockers. Monitor for peripheral neuropathy and seizure with prolonged use. Disulfiram-like reaction occurs with alcohol; counsel patients to avoid alcohol during therapy and for 48 hours after last dose. Use caution in hepatic impairment (dose reduction recommended). Intravenous form is irritant; do not co-administer with blood products via same line.
Combination of chloroquine and primaquine is used for radical cure of P. vivax and P. ovale malaria. Chloroquine is effective against blood-stage parasites; primaquine eradicates hypnozoites in the liver. Screen for G6PD deficiency before initiating primaquine to prevent hemolytic anemia. Concurrent use with hematotoxic drugs (e.g., dapsone) increases hemolysis risk. Contraindicated in G6PD-deficient patients, pregnancy, and breastfeeding unless no alternative. Monitor for QT prolongation, especially with electrolyte abnormalities or concurrent QT-prolonging agents.
Avoid alcohol and alcohol-containing products during treatment and for 48 hours after the last dose to prevent severe nausea, vomiting, and flushing.,Take with food to minimize gastrointestinal upset.,Complete the full course even if symptoms improve.,Report numbness, tingling, or seizures immediately.,May cause metallic taste (harmless) and darkening of urine (not clinically significant).
Take with food or milk to reduce gastrointestinal upset.,Complete full course regardless of symptom resolution to prevent relapse.,Avoid alcohol during treatment due to risk of disulfiram-like reaction.,Report signs of hemolysis: dark urine, jaundice, pallor, fatigue (especially if G6PD deficient).,Do not take antacids containing magnesium or aluminum within 4 hours of chloroquine as they reduce absorption.,Seek medical attention for visual disturbances, QT prolongation symptoms (palpitations, syncope), or severe GI distress.,Use effective contraception during and for 1 month after treatment due to potential fetal harm from primaquine.
"Metronidazole is a known inhibitor of CYP3A4, the primary enzyme responsible for metabolizing Osimertinib. Coadministration increases Osimertinib AUC by approximately 30-60%, leading to elevated plasma concentrations that may potentiate adverse effects such as QTc prolongation, interstitial lung disease, and diarrhea. Clinicians should monitor for signs of Osimertinib toxicity and consider dose reduction if concurrent use is unavoidable."
"Metronidazole inhibits CYP3A4, the primary enzyme responsible for the metabolism of ergotamine. Co-administration can lead to significantly elevated ergotamine plasma concentrations, increasing the risk of ergotism—a serious condition characterized by severe vasoconstriction, ischemia, and potential gangrene of the extremities. Patients may present with symptoms such as cold, painful extremities, muscle pain, and paresthesias, requiring immediate intervention."
"Levofloxacin and metronidazole both prolong the QT interval, and their concurrent use can lead to additive effects on cardiac repolarization. This increases the risk of torsade de pointes, a potentially fatal ventricular arrhythmia. Patients with pre-existing QT prolongation, electrolyte disturbances, or bradycardia are at higher risk."
"Alimemazine, a phenothiazine derivative with antihistaminergic and anticholinergic properties, may inhibit the metabolism of Primaquine, an antimalarial agent primarily metabolized by cytochrome P450 enzymes including CYP2D6 and CYP3A4. This interaction can lead to increased plasma concentrations of Primaquine, heightening the risk of dose-dependent adverse effects such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and methemoglobinemia. Clinically, patients may present with signs of oxidant stress, including hemoglobinuria and jaundice."
"Eliglustat, a CYP2D6 substrate and inhibitor, can increase the systemic exposure of primaquine, which is primarily metabolized by CYP2D6. This elevation in primaquine concentration may potentiate its QTc-prolonging effects, leading to an increased risk of torsades de pointes and other ventricular arrhythmias. Caution is advised, especially in patients with pre-existing cardiac conditions or electrolyte abnormalities."
"Primaquine, an antimalarial agent, can inhibit the cardiac potassium channel encoded by the hERG gene, leading to prolongation of the QTc interval. Ivabradine, a funny current (If) inhibitor used for chronic heart failure, also possesses a mild QTc-prolonging effect. Concomitant use increases the risk of excessive QTc prolongation, which may precipitate torsade de pointes and other ventricular arrhythmias, particularly in patients with underlying risk factors such as electrolyte disturbances or bradycardia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METRONIDAZOLE vs ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE, answered by our medical review team.
METRONIDAZOLE is a Nitroimidazole Antibiotic that works by After entry into the cell, metronidazole is reduced by bacterial nitroreductases to form toxic metabolites that damage DNA and inhibit nucleic acid synthesis, leading to cell death.. ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is a Antimalarial that works by Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METRONIDAZOLE and ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METRONIDAZOLE is: 500 mg intravenously every 8 hours or 500 mg orally every 8 hours; for bacterial vaginosis, 500 mg orally twice daily for 7 days; for trichomoniasis, 2 g orally as a single dose.. The standard adult dose of ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is: Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining METRONIDAZOLE and ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE. Primaquine may increase the QTc-prolonging activities of Metronidazole. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. METRONIDAZOLE is classified as Category A/B. Metronidazole crosses the placenta. First trimester: limited human data show no consistent increase in major malformations; however, some studies suggest a possible small risk of o. ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is classified as Category D/X. In first trimester, chloroquine is generally considered low risk for major malformations, but primaquine is contraindicated due to risk of hemolytic anemia in G6PD-deficient fetuse. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.